Be Ready When Your Crohn's Disease Patients Start Biologics

July 2018

You'll see biologics considered earlier for Crohn's disease...partly due to new guidelines from the Am College of Gastroenterology.

This "top-down" approach is becoming more popular...versus waiting to see if meds such as sulfasalazine, mesalazine, or corticosteroids help.

For Crohn's, anticipate seeing infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), vedolizumab (Entyvio), etc. These can lead to faster and longer-lasting remission for some higher-risk patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Sunscreens Help Balance Competing Concerns About Sunscreens
Aspirin Put the Aspirin and NSAID Interaction in Perspective
Diabetes Don't Recommend a Flozin Plus GLP-1 Agonist for Most Diabetes Patients
Women's Health Consider Both Mom and Baby When Treating Hypertension in Pregnancy
Crohn's Disease Be Ready When Your Crohn's Disease Patients Start Biologics
Stroke Optimize Meds to Reduce Recurrent Stroke Risk
Psychiatry Recommend Bipolar Treatment Based on the New Guideline Ranking System
Practice Set Patient Expectations for Home Genetic Tests
Communication Improve Communication With Older Patients
Anticoagulants Reassure Patients That Liver Injury With Oral Anticoagulants Is Rare

Be Ready When Your Crohn's Disease Patients Start Biologics

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents